LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

T-Cell CD27 Expression Assessed for Smear-Negative Tuberculosis

By LabMedica International staff writers
Posted on 27 Jul 2021
Print article
Image: The Cytomics FC500 Flow Cytometer System (Photo courtesy of Beckman Coulter Life Sciences)
Image: The Cytomics FC500 Flow Cytometer System (Photo courtesy of Beckman Coulter Life Sciences)
Mycobacterium tuberculosis (MTB) and its related disease tuberculosis (TB) are infectious diseases with a worldwide focus. Although both vaccines and anti-TB drugs are available, there is a global focus on illness diagnosis in smear-negative and latent tuberculosis infectious populations (SN-TB and LTBI).

To a great extent, the cell-mediated immune response is involved in and regulates MTB, and CD4 T cells are thought to play a significant role in controlling MTB infection. CD27, a member of the TNF-receptor superfamily, is inextricably expressed on the mature pathogen-specific CD4+ T cell surface.

Pathogen Biologists at Nantong University (Nantong, China) and their colleagues include in a study 56 SN-TB patients, all had negative detection of sputum at least three times and sputum negative-culture results; an human control (HC) group that included 34 participants with no exposure to MTB and no clinical characteristics of TB, and the Tuberculosis Skin Test (PPD) test was negative; and 46 doctors and nurses working closely with TB patients for at least 1 year (TB-C group.)

All 56 smear-negative TB patients included in the study had peripheral blood collected and sputum collected at least three times for Ziehl-Neelsen acid-fast stain. Sputum culture was carried out by BACTEC MGIT 960 (Becton Dickinson, Sparks, MD, USA), liquid culture isolates using the GenoTypeH test system (Hain Lifescience, Nehren, Germany) and improved L-J culture medium. T-SPOT (tuberculosis infectious T-lymphocyte spot assay, Oxford Immunotec, Abingdon, UK) results were obtained from the clinical laboratory. For detection of the whole blood cell surface markers “CD27−CD4+” T cells, cells were collected, washed and analyzed by a Beckman Coulter FC500 flow cytometry analysis system (Indianapolis, IN, USA).

The scientists observed that the percentages of “CD27−IFN-γ+CD4+” cells were significantly increased in the SN-TB group compared with the HC and TB-C groups (AUC was 0.88, sensitivity was 82.14%, and specificity was 80.0%). The percentage of “CD27−IFN-γ+CD4+” cells was negatively correlated with white blood cell count (WBC) and positively correlated with immunoglobulin E (IgE). Furthermore, “CD27−IFN-γ+CD4+” cells were significantly decreased, especially in the > 50 years group, after clinical treatment.

The authors concluded that they had demonstrated the increased expression of “CD27−IFN-γ+CD4+” cells in smear-negative TB patients and evaluated its changes after normal anti-TB therapy. These data suggested that “CD27−IFN-γ+CD4+” T cells could be used to assist the diagnosis of TB and more accurately evaluate the treatment outcome of smear-negative TB. The study was published on June 27, 2021 in the journal BMC Immunology.

Related Links:
Nantong University
Becton Dickinson
Hain Lifescience
Oxford Immunotec
Beckman Coulter


Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.